Ka-Ching... Greffex to Build the First Comprehensive H7N9 Vaccine
In just one month after the virus had been characterized, Greffex scientists built an H7N9 avian influenza vaccine using its proprietary GREVAXTM technology. Normally development of such a vaccine takes many months. We believe the world needs a plug-and-play TM method of creating vaccines, says Greffex Chief Scientific Officer Dr. Uwe D. Staerz. Speed as well as flexibility is needed for vaccine design to combat emerged infectious threats. We had already shown with an Anthrax vaccine that we can create ANY vaccine within one month.